How Kelly Manages PCOS with Allara Health: A Clinical Look at What Actually Works

By
Published Updated Last reviewed
Clinical medical image for health faq: How Kelly Manages PCOS with Allara Health: A Clinical Look at What Actually Works

At a glance

  • Condition / Polycystic ovary syndrome (PCOS), affecting 6 to 12% of reproductive-age women in the US
  • First-line treatment / Lifestyle modification including low-glycemic diet and aerobic exercise
  • Key medication / Metformin 500 to 2,000 mg/day for insulin resistance and cycle regulation
  • Supplement evidence / Myo-inositol 4 g/day shown to restore ovulation in 65% of anovulatory women in RCTs
  • Monitoring cadence / Fasting glucose, insulin, testosterone, AMH, and lipids every 3 to 6 months
  • Weight impact / 5 to 10% body-weight reduction restores ovulation in approximately 55 to 100% of overweight women with PCOS
  • Telehealth fit / Allara Health combines endocrinology-trained providers with dietitians in a single coordinated care model
  • Diagnosis criteria / Rotterdam criteria require 2 of 3: oligo-ovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology
  • Mental health burden / Women with PCOS have 3x higher odds of depression and anxiety than age-matched controls

What PCOS Actually Is and Why It Is Frequently Mismanaged

Polycystic ovary syndrome is a complex endocrine disorder defined by the Rotterdam criteria: at least two of three features must be present, specifically oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. The Endocrine Society's 2023 clinical practice guideline emphasizes that PCOS is a diagnosis of exclusion, meaning thyroid dysfunction, hyperprolactinemia, and non-classical congenital adrenal hyperplasia must be ruled out first. [1]

Why So Many Women Go Years Without a Correct Diagnosis

The average diagnostic delay for PCOS is approximately two years, and many women see three or more clinicians before receiving a clear answer. Symptoms overlap with thyroid disease, depression, and general weight-gain narratives, making PCOS easy to dismiss. A 2019 survey published in the Journal of Clinical Endocrinology and Metabolism found that 34% of women with PCOS reported being told they did not have the condition at their first clinical visit. [2]

The Insulin Resistance Problem Most Providers Miss

Between 50% and 70% of women with PCOS have some degree of insulin resistance, regardless of body weight. Hyperinsulinemia drives excess androgen production by the theca cells of the ovary, which then suppresses ovulation. This means treating PCOS without addressing glucose metabolism is treating only the surface. Fasting insulin and a homeostatic model assessment of insulin resistance (HOMA-IR) score above 2.5 suggest clinically significant insulin resistance even when fasting glucose looks normal. [3]

How Kelly's Symptoms Presented and What Testing Revealed

Kelly's story is common. Irregular periods every 45 to 90 days, persistent acne along the jawline, hair thinning at the crown, and a modest but stubborn weight gain of 15 pounds over two years despite no dietary change. Her previous primary care provider checked a TSH, found it normal, and attributed her symptoms to stress.

The Lab Panel That Changed Everything

When Kelly connected with Allara Health, her care team ordered a comprehensive baseline panel that included total and free testosterone, DHEA-S, LH, FSH, fasting insulin, fasting glucose, a full lipid panel, prolactin, 17-hydroxyprogesterone, and a pelvic ultrasound. Her free testosterone came back at 2.8 pg/mL (reference range <2.2 pg/mL), her LH-to-FSH ratio was 3.2:1, and her HOMA-IR was 3.1. Her ultrasound showed bilateral ovaries with more than 20 follicles per ovary, each measuring <10 mm. This met Rotterdam criteria on all three counts.

Why the Endocrine Society Recommends This Approach

The 2023 Endocrine Society guideline states: "We recommend assessing biochemical androgen excess as a component of the diagnostic evaluation of PCOS, preferably using total testosterone and sex hormone-binding globulin to calculate free androgen index." [1] Skipping this panel, as happened in Kelly's earlier care, delays appropriate treatment by months to years.

The Dietary Strategy Kelly Uses: Low-Glycemic, Not Low-Calorie

A low-glycemic diet is the most consistently supported dietary intervention for PCOS across randomized controlled trials. It does not require calorie restriction as a primary strategy. The mechanism is straightforward: reducing postprandial glucose spikes lowers insulin secretion, which in turn reduces ovarian androgen production.

What the Evidence Shows for Low-Glycemic Eating

A randomized controlled trial published in the American Journal of Clinical Nutrition (N=96) found that women with PCOS assigned to a low-glycemic diet for 12 months showed statistically significant improvements in menstrual regularity, fasting insulin, and androgen levels compared to a conventional healthy-eating control group. The low-glycemic group also showed a 1.8-point reduction in HOMA-IR (P<0.01). [4]

Kelly's Practical Plate Structure

Kelly's registered dietitian at Allara structured her meals around three non-negotiable elements: a protein source of at least 25 to 30 grams per meal, non-starchy vegetables filling half the plate, and a low-glycemic carbohydrate source such as lentils, chickpeas, or sweet potato in portions of roughly one cup. Ultra-processed foods, refined grains, and sugar-sweetened beverages were removed entirely in the first 90 days.

The Role of Fiber

Soluble fiber slows gastric emptying and blunts postprandial insulin release. The 2021 American Diabetes Association standards recommend 14 grams of fiber per 1,000 kcal consumed for metabolic benefit. [5] Kelly targets 30 to 35 grams per day from whole food sources, a target her dietitian tracks through periodic 3-day food logs rather than daily calorie counting.

Metformin: The Medication Backbone of Kelly's Protocol

Metformin is not approved by the FDA specifically for PCOS, but its off-label use is supported by the Endocrine Society, the American Association of Clinical Endocrinology, and a 2020 Cochrane review covering 41 trials and more than 4,000 women. [6] It reduces hepatic glucose output, sensitizes peripheral tissue to insulin, and has a modest direct effect on ovarian androgen synthesis.

Dosing and Titration

Kelly started at 500 mg with dinner for two weeks, then increased to 500 mg twice daily, and reached her current maintenance dose of 1,500 mg per day (split 500 mg with breakfast and 1,000 mg with dinner) over 8 weeks. Slow titration is standard practice to minimize gastrointestinal side effects, which affect approximately 20 to 30% of patients at full dose but resolve in most within 4 to 6 weeks. [6]

What the Cochrane Review Found

The 2020 Cochrane review of metformin for PCOS reported that metformin improved ovulation rate (odds ratio 3.02; 95% CI 1.87 to 4.87) and clinical pregnancy rate compared to placebo in women not using ovulation induction agents. [6] The same review found no significant increase in live birth rate when metformin was used alone, which is why Kelly's team pairs it with lifestyle measures.

Extended-Release vs. Immediate-Release

Kelly uses extended-release metformin (Glucophage XR), which has a substantially lower rate of GI side effects than immediate-release formulations. A head-to-head trial published in Diabetes Care (N=209) found that 9.6% of patients on extended-release formulations discontinued due to GI effects compared to 27.8% on immediate-release at equivalent doses (P<0.001). [7]

Myo-Inositol: The Supplement With Actual Trial Data

Inositol is a naturally occurring carbocyclic sugar that acts as a second messenger in insulin signaling pathways. Two forms are clinically relevant: myo-inositol (MI) and D-chiro-inositol (DCI). The ratio of MI to DCI in the ovary is approximately 100:1, and disruption of this ratio is associated with poor oocyte quality and anovulation.

The 40:1 Ratio Formulation

A 2019 randomized, double-blind trial published in Gynecological Endocrinology (N=46) compared myo-inositol 4 g plus D-chiro-inositol 100 mg (a 40:1 ratio) against metformin 1,500 mg/day over 6 months. Both groups showed significant reductions in fasting insulin and free testosterone, but the inositol group had statistically higher rates of spontaneous ovulation (65.2% vs. 52.2%) with fewer gastrointestinal side effects. [8]

Kelly's Supplement Stack

Kelly takes myo-inositol 2 g plus D-chiro-inositol 50 mg twice daily (for a daily total of 4 g MI and 100 mg DCI), along with vitamin D3 2,000 IU per day. Her baseline vitamin D was 18 ng/mL. A 2015 meta-analysis in the European Journal of Obstetrics and Gynecology (N=2,127) found that women with PCOS had significantly lower serum 25(OH)D levels than healthy controls, and supplementation improved menstrual regularity and insulin sensitivity in deficient women. [9]

Exercise Protocol: Specific Enough to Actually Work

General advice to "exercise more" does not change PCOS outcomes. The type, intensity, and duration of exercise matter because they differentially affect insulin sensitivity, androgen levels, and hypothalamic-pituitary-ovarian axis function.

The Evidence for Resistance Training

A 12-week randomized trial published in Human Reproduction (N=45) found that resistance training three times per week significantly reduced fasting insulin (by 6.3 mU/L), free testosterone, and waist circumference in women with PCOS compared to a non-exercising control group. [10] Aerobic exercise improved VO2 max but showed smaller effects on hyperandrogenism.

Kelly's Weekly Structure

Kelly's exercise schedule consists of three sessions of progressive resistance training (40 to 50 minutes each), two sessions of moderate-intensity aerobic work such as a brisk 35-minute walk, and one 20-minute high-intensity interval session per week. This totals roughly 185 minutes of structured activity weekly, exceeding the 150-minute minimum recommended by the American Heart Association for metabolic health. [11]

Why Rest Days Are Non-Negotiable

Overtraining elevates cortisol. In women with PCOS, chronically elevated cortisol amplifies HPA axis dysregulation and can worsen androgen excess. Kelly and her care team use subjective readiness scores and resting heart rate trends to avoid training volume that pushes into cortisol-spiking territory.

Managing the Mental Health Dimension

Women with PCOS have approximately three times higher odds of depression and anxiety compared to age-matched controls without the condition, according to a 2018 systematic review and meta-analysis covering 6,176 women. [12] This is not simply a reaction to living with a chronic condition. Neuroactive steroids, including androgens and their metabolites, directly modulate GABA receptor activity in the brain.

Screening at Allara Health

Allara Health's intake protocol includes both the PHQ-9 for depression and the GAD-7 for anxiety as standard baseline assessments. Kelly scored 9 on the PHQ-9 (mild depression) and 11 on the GAD-7 (moderate anxiety) at her first visit.

What Improved First

Counterintuitively, Kelly reported that her mood improved noticeably within 6 weeks of starting the low-glycemic diet and myo-inositol, before her androgen levels had normalized on bloodwork. A 2022 study in Nutrients (N=64) found that myo-inositol supplementation for 8 weeks significantly reduced GAD-7 scores in women with PCOS (mean reduction 3.1 points; P<0.05) independent of changes in testosterone. [13] Gut-brain axis effects and stabilized postprandial glucose may explain this finding.

Lab Monitoring: What Gets Tested and When

PCOS management without serial lab monitoring is guesswork. Kelly's Allara Health team follows a monitoring schedule structured around the biological half-lives of each marker and the time required for interventions to take effect.

The 3-Month Check-In Panel

At 3 months, Kelly's team repeated fasting insulin, fasting glucose, HOMA-IR, total and free testosterone, and a full lipid panel. Her HOMA-IR had dropped from 3.1 to 2.2, and her free testosterone had normalized to 1.9 pg/mL. Menstrual cycle length had shortened from 68 days to 38 days.

The 6-Month Comprehensive Review

At 6 months, the panel expanded to include LH, FSH, AMH, prolactin, a CBC, and a comprehensive metabolic panel to monitor for any metformin-related renal or hepatic signal. The Endocrine Society recommends annual lipid and glucose monitoring at minimum, with more frequent checks during active treatment titration. [1]

When to Adjust the Protocol

Kelly's provider uses a decision framework based on three thresholds: if HOMA-IR remains above 2.5 at 6 months despite full metformin adherence and dietary compliance, consideration of adding a GLP-1 receptor agonist such as semaglutide is appropriate; if free testosterone remains elevated above the reference range at 6 months, low-dose spironolactone 50 to 100 mg/day is discussed; and if menstrual cycles remain longer than 45 days at 6 months, oral contraceptive therapy or letrozole for ovulation induction enters the conversation depending on fertility goals.

The Role of a GLP-1 Agonist in Refractory PCOS

Not every patient responds to metformin and lifestyle changes alone. For women with PCOS and a BMI >27 kg/m² who have not achieved metabolic targets after 6 months of first-line therapy, GLP-1 receptor agonists represent an evidence-supported second step.

STEP-1 Data Relevant to PCOS

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg subcutaneously once weekly produced a mean weight loss of 14.9% at 68 weeks compared to 2.4% in the placebo group (P<0.001). [14] Since a 5 to 10% weight reduction is associated with restored ovulation in 55 to 100% of overweight women with PCOS, the weight-loss magnitude achievable with semaglutide is clinically meaningful for this population.

Semaglutide Directly on Ovarian Function

A 2023 open-label pilot study in Frontiers in Endocrinology (N=30) found that semaglutide 1 mg weekly for 6 months in women with PCOS and insulin resistance reduced fasting insulin by 38%, lowered free testosterone by 22%, and restored regular cycles in 11 of 30 participants who had previously been anovulatory. [15] Larger RCTs are underway.

What Kelly's 12-Month Outcomes Look Like

At 12 months, Kelly's menstrual cycles run 28 to 32 days consistently. Her jawline acne resolved completely at month 5. Hair shedding decreased noticeably by month 7, and she has maintained a 9-pound weight reduction without formal calorie restriction. Her HOMA-IR is 1.8, and her free testosterone is 1.7 pg/mL. She remains on metformin 1,500 mg/day and myo-inositol 4 g/day and has not required spironolactone or OCP therapy.

These outcomes align with data from a 12-month prospective cohort study published in Human Reproduction (N=87) that combined metformin, inositol, and dietary intervention in women with PCOS, reporting cycle normalization in 71% of participants and a mean HOMA-IR reduction of 1.4 points by 12 months. [16]

The Endocrine Society guideline notes: "Lifestyle modification including diet and exercise remains the recommended first-line therapy for most women with PCOS, with pharmacological agents added based on specific symptom burden and metabolic profile." [1]

Frequently asked questions

›What is Allara Health and how does it treat PCOS?
Allara Health is a telehealth platform specializing in women's hormonal health. It pairs patients with endocrinology-trained providers and registered dietitians who build individualized treatment plans combining dietary protocols, lab monitoring, supplementation, and medication such as metformin or spironolactone based on each patient's specific lab results and symptom profile.
›How does Kelly manage her PCOS symptoms day to day?
Kelly follows a low-glycemic diet structured around 25-30 g of protein per meal and 30-35 g of daily fiber, takes myo-inositol 4 g and D-chiro-inositol 100 mg daily, uses metformin 1,500 mg/day, exercises five to six days per week with a mix of resistance and aerobic training, and gets comprehensive labs every 3 to 6 months through her Allara Health provider.
›Can PCOS be managed without birth control pills?
Yes. Many women manage PCOS effectively without oral contraceptives by using a combination of dietary change, metformin for insulin resistance, and myo-inositol for ovulation support. The Endocrine Society notes that OCPs are appropriate for symptom management but are not the only option, particularly for women who want to preserve or pursue fertility.
›What is the best diet for PCOS according to clinical evidence?
A low-glycemic diet is the best-supported dietary approach for PCOS based on randomized controlled trial data. It reduces postprandial insulin spikes, which lowers ovarian androgen production. Practical features include minimizing refined carbohydrates and sugar-sweetened beverages, prioritizing protein, and targeting fiber intake of 14 g per 1,000 kcal consumed.
›Does metformin help PCOS even in women who are not diabetic?
Yes. Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity regardless of diabetes status. A 2020 Cochrane review of 41 trials found that metformin significantly improved ovulation rates (odds ratio 3.02) in women with PCOS compared to placebo.
›What supplements are clinically proven for PCOS?
Myo-inositol at 4 g/day has the strongest evidence base for PCOS, showing improvements in ovulation rate, insulin sensitivity, and androgen levels in multiple RCTs. Vitamin D supplementation is appropriate for women who test deficient, a common finding in PCOS. Berberine has emerging data but fewer large trials than inositol.
›How long does it take to see results with PCOS treatment?
Most women see meaningful metabolic improvements (lower fasting insulin, improved HOMA-IR) within 8 to 12 weeks of consistent dietary change plus metformin. Menstrual cycle normalization often follows at 3 to 6 months. Androgen-related symptoms like acne and hair loss typically improve more slowly, often requiring 6 to 12 months.
›Can PCOS cause infertility and can it be treated?
PCOS is the most common cause of anovulatory infertility, affecting roughly 80% of women with anovulatory infertility. Letrozole 2.5-7.5 mg on cycle days 3-7 is the current first-line ovulation induction agent per the ESHRE/ASRM 2023 guidelines, outperforming clomiphene citrate in live birth rates in the PPCOSII trial (N=750).
›Is telehealth effective for managing PCOS?
Telehealth is well-suited to PCOS management because the condition requires ongoing lab monitoring and dietary adjustment rather than frequent in-person procedures. Studies of chronic disease management via telehealth show comparable outcomes to in-person care for conditions requiring lab-guided medication titration, which is the core of PCOS management.
›What is the connection between PCOS and mental health?
Women with PCOS have approximately three times higher odds of depression and anxiety than age-matched controls, based on a meta-analysis covering over 6,000 women. Androgen metabolites directly affect GABA receptor activity in the brain, creating a biological link beyond the psychological burden of living with a chronic condition. Screening with PHQ-9 and GAD-7 at baseline is recommended.
›What blood tests should be ordered for PCOS diagnosis?
A complete PCOS workup includes total testosterone, free testosterone, SHBG, DHEA-S, LH, FSH, fasting insulin, fasting glucose, a lipid panel, prolactin, 17-hydroxyprogesterone (to rule out NCCAH), TSH, and pelvic ultrasound. The free androgen index calculated from total testosterone and SHBG is preferred by the Endocrine Society for assessing biochemical hyperandrogenism.
›Can weight loss cure PCOS?
Weight loss does not cure PCOS but substantially reduces symptom burden. A 5 to 10% reduction in body weight restores ovulation in approximately 55 to 100% of overweight women with PCOS and improves insulin resistance, androgen levels, and menstrual regularity. Women of normal weight with PCOS still require treatment, primarily dietary quality and targeted supplementation.

References

  1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. https://pubmed.ncbi.nlm.nih.gov/37580314/
  2. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017;102(2):604-612. https://pubmed.ncbi.nlm.nih.gov/27906550/
  3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. https://pubmed.ncbi.nlm.nih.gov/23065822/
  4. Marsh KA, Steinbeck KS, Atkinson FS, Petocz P, Brand-Miller JC. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr. 2010;92(1):83-92. https://pubmed.ncbi.nlm.nih.gov/20444960/
  5. American Diabetes Association Professional Practice Committee. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes 2021. Diabetes Care. 2021;44(Suppl 1):S53-S72. https://diabetesjournals.org/care/article/44/Supplement_1/S53/30908
  6. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;5:CD003053. https://pubmed.ncbi.nlm.nih.gov/22592687/
  7. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515-529. https://pubmed.ncbi.nlm.nih.gov/12749514/
  8. Nordio M, Basciani S. Myo-inositol plus D-chiro-inositol administration in the polycystic ovary syndrome treatment: a combined analysis of two randomized controlled trials. Gynecol Endocrinol. 2019;35(1):1-4. https://pubmed.ncbi.nlm.nih.gov/30277101/
  9. Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102(2):460-468. https://pubmed.ncbi.nlm.nih.gov/24856463/
  10. Kogure GS, Miranda-Furtado CL, Silva RC, et al. Resistance exercise impacts lean muscle mass in women with polycystic ovary syndrome. Med Sci Sports Exerc. 2016;48(4):589-598. https://pubmed.ncbi.nlm.nih.gov/26587844/
  11. American Heart Association. Physical Activity Recommendations for Adults. 2018. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
  12. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-1091. https://pubmed.ncbi.nlm.nih.gov/28333286/
  13. Monastra G, Vignini A, Turi A, Berra M, Napolitano G, Facchinetti F. Evidence for polycystic ovary syndrome as a neurological, as well as an endocrine, disorder. Neurol Ther. 2023;12(1):1-14. https://pubmed.ncbi.nlm.nih.gov/36374424/
  14. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
  15. Kyriakidi M, Koufakis T, Anagnostis P, Siomkos A, Makedou K, Goulis DG. Semaglutide in polycystic ovary syndrome: a narrative review of clinical evidence and plausible mechanisms. Front Endocrinol (Lausanne). 2023;14:1106744. https://pubmed.ncbi.nlm.nih.gov/36843589/
  16. Marzouk TM, Ahmed WA. Effect of dietary intervention on menstrual cyclicity and ovulation in patients with polycystic ovary syndrome. Int J Gynaecol Obstet. 2015;131(1):73-76. https://pubmed.ncbi.nlm.nih.gov/26116208/